Lutikizumab  (Synonyms: ABT-981)

Lutikizumab (ABT-981) is an anti-IL-1α and IL-1β dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1α and IL-1β. Lutikizumab can be used for the research of osteoarthritis^[1].

[VH-VH'-H-Gamma1_VL-VL'-C-kappa]-dimer

Human IgG1 kappa, Isotype Control

Human

IL-1a & IL1b

ABT-981 shows simultaneously binding efficacy human IL-α and IL-1β molecules^[1].
ABT-981 shows highly specific binding effects to IL-α and IL-1β over other IL-1 family members^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Lutikizumab (0.0001-1 mg/kg, i.p., once) shows effective inhibition to the IL-6 production induced by IL-1α and IL-1β^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3552  [NCBI] & 3553  [NCBI]

P01583 & P01584

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

196.57 kDa

1791411-57-8

Liquid

Colorless to light yellow

[Lutikizumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [VH-VH'-H-Gamma1_VL-VL'-C-kappa]-dimer

• 
  Immobilized Human IL-1 alpha/IL1A Protein can bind Lutikizumab. The EC₅₀ for this effect is 1.97 ng/mL.
• 
  Immobilized Human IL-1 beta Protein can bind Lutikizumab. The EC₅₀ for this effect is 3.63 ng/mL.

• [1]. Lacy SE, et al. Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β. MAbs. 2015;7(3):605-19.  [Content Brief]